M. Robert Cooper

9.7k total citations · 4 hit papers
138 papers, 7.3k citations indexed

About

M. Robert Cooper is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Robert Cooper has authored 138 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 31 papers in Pathology and Forensic Medicine and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Robert Cooper's work include Cancer Treatment and Pharmacology (24 papers), Lymphoma Diagnosis and Treatment (21 papers) and Multiple Myeloma Research and Treatments (16 papers). M. Robert Cooper is often cited by papers focused on Cancer Treatment and Pharmacology (24 papers), Lymphoma Diagnosis and Treatment (21 papers) and Multiple Myeloma Research and Treatments (16 papers). M. Robert Cooper collaborates with scholars based in United States, Switzerland and Malaysia. M. Robert Cooper's co-authors include Lawrence R. DeChatelet, Hyman B. Muss, Charles L. Spurr, Randal R. Nixon, P C Comp, Charles T. Esmon, George P. Canellos, James R. Anderson, Edward S. Henderson and B. A. Peterson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

M. Robert Cooper

137 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

2003 921 citations M. Robert Cooper, James F. Holland et al. Journal of Clinical Oncology profile →
Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

1992 813 citations George P. Canellos, James R. Anderson et al. profile →
Lack of Effect of a Low-Fat, High-Fiber Diet on the Recurrence of Colorectal Adenomas

2000 640 citations M. Robert Cooper et al. profile →
Familial protein S deficiency is associated with recurrent thrombosis.

1984 488 citations M. Robert Cooper et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Robert Cooper United States	37	3.4k	1.7k	1.5k	1.3k	1.0k	138	7.3k
Martin D. Abeloff United States	41	3.1k 0.9×	804 0.5×	1.8k 1.2×	988 0.8×	694 0.7×	119	6.4k
Thomas E. Moon United States	41	2.3k 0.7×	1.3k 0.8×	632 0.4×	1.4k 1.1×	491 0.5×	107	7.9k
Pierre Biron France	50	4.7k 1.4×	4.5k 2.6×	461 0.3×	1.7k 1.3×	1.6k 1.5×	292	10.6k
Harmon J. Eyre United States	39	4.2k 1.2×	1.2k 0.7×	783 0.5×	1.9k 1.5×	180 0.2×	95	8.6k
Howard Ozer United States	38	2.6k 0.8×	860 0.5×	348 0.2×	600 0.5×	1.2k 1.2×	143	5.5k
Timothy Perren United Kingdom	42	3.0k 0.9×	806 0.5×	873 0.6×	902 0.7×	461 0.4×	151	6.6k
R. Kreienberg Germany	54	4.3k 1.3×	1.5k 0.8×	3.4k 2.2×	1.3k 1.0×	211 0.2×	434	10.6k
M. Schneider France	38	2.8k 0.8×	528 0.3×	316 0.2×	1.3k 1.0×	1.2k 1.2×	108	5.8k
Laura F. Hutchins United States	40	4.0k 1.2×	700 0.4×	1.5k 1.0×	1.7k 1.3×	285 0.3×	121	7.2k
Stig E. Bojesen Denmark	50	1.8k 0.5×	1.2k 0.7×	1.7k 1.1×	1.4k 1.1×	454 0.4×	172	8.3k

Countries citing papers authored by M. Robert Cooper

Since Specialization

Citations

This map shows the geographic impact of M. Robert Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Robert Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Robert Cooper more than expected).

Fields of papers citing papers by M. Robert Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Robert Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Robert Cooper. The network helps show where M. Robert Cooper may publish in the future.

Co-authorship network of co-authors of M. Robert Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of M. Robert Cooper. A scholar is included among the top collaborators of M. Robert Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Robert Cooper. M. Robert Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Katz, Mira L., Cathy M. Tatum, Stephanie Dickinson, et al.. (2007). Improving colorectal cancer screening by using community volunteers. Cancer. 110(7). 1602–1610. 33 indexed citations

Kimmick, Gretchen, Brent J. Shelton, L. Douglas Case, M. Robert Cooper, & Hyman B. Muss. (2002). Long-Term Follow-Up of a Phase II Trial Studying a Weekly Doxorubicin-Based Multiple Drug Adjuvant Therapy for Stage II Node-Positive Carcinoma of the Breast. Breast Cancer Research and Treatment. 72(3). 233–243. 9 indexed citations

Cameron, Christine L., David Cella, James E. Herndon, et al.. (2001). Persistent symptoms among survivors of Hodgkin's disease: An explanatory model based on classical conditioning.. Health Psychology. 20(1). 71–75. 17 indexed citations

Ricketts, Thomas C., et al.. (1999). Rural breast cancer treatment: evidence from the Reaching Communities for Cancer Care (REACH) project. Breast Cancer Research and Treatment. 56(1). 59–66. 40 indexed citations

Ozer, Howard, James R. Anderson, B. A. Peterson, et al.. (1994). Combination trial of subcutaneous recombinant α₂b interferon and oral cyclophosphamide in follicular low‐grade non‐Hodgkin's lymphoma. Medical and Pediatric Oncology. 22(4). 228–235. 11 indexed citations

Vogelzang, Nicholas J., et al.. (1994). Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.. Journal of Clinical Oncology. 12(7). 1436–1442. 67 indexed citations

Pluda, James M., Andrea Foli, Steven R. Tannenbaum, et al.. (1993). Administration of Pentosan Polysulfate to Patients With Human Immunodeficiency Virus-Associated Kaposi's Sarcoma. JNCI Journal of the National Cancer Institute. 85(19). 1585–1592. 48 indexed citations

Anderson, James R., David Cella, Susan Tross, et al.. (1992). Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. Cancer. 70(8). 2214–2224. 123 indexed citations

Schulman, Philip, Kathleen McCarroll, M. Robert Cooper, et al.. (1990). Phase II study of moplace chemotherapy for patients with previously treated Hodgkin's disease: A calgb study. Medical and Pediatric Oncology. 18(6). 482–486. 16 indexed citations

10.

Michielutte, Robert, et al.. (1990). Evaluation of an oncology curriculum. Journal of Cancer Education. 5(1). 37–41. 2 indexed citations

11.

Buss, David H., Robert W. Prichard, & M. Robert Cooper. (1988). Plasma Cell Dyscrasias. Hematology/Oncology Clinics of North America. 2(4). 603–615. 5 indexed citations

12.

Richards, Fred, L. Douglas Case, Dougľas R. White, et al.. (1986). Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.. Journal of Clinical Oncology. 4(4). 565–570. 23 indexed citations

13.

Powell, Bayard L., Don V. Jackson, Charles W. Scarantino, et al.. (1985). Sequential hemibody and local irradiation with combination chemotherapy for small cell lung carcinoma: A preliminary analysis. International Journal of Radiation Oncology*Biology*Physics. 11(3). 457–462. 10 indexed citations

14.

Jackson, Don V., Eugene Paschold, Charles L. Spurr, et al.. (1984). Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer. 53(12). 2601–2606. 36 indexed citations

15.

Jackson, Don V., H. Bradley Wells, Dougľas R. White, et al.. (1983). Lack of potentiation of vincristine-induced neurotoxicity by VP-16–213. American Journal of Clinical Oncology. 6(3). 327–330. 13 indexed citations

16.

Cooper, M. Robert, Thomas F. Pajak, Nis I. Nissen, et al.. (1982). Effect of the methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease. Cancer. 49(11). 2226–2230. 5 indexed citations

17.

Muss, Hyman B., Frederick Richards, M. Robert Cooper, et al.. (1982). Nonseminomatous germ cell cancer of the testis. Reducing treatment-related morbidity in patients with disseminated disease. Cancer. 50(9). 1742–1745. 4 indexed citations

18.

Richards, Frederick, Virginia J. Howard, Hyman B. Muss, et al.. (1981). Combination chemotherapy with and without the methanol-extracted residue of bacillus calmette-guerin (MER) in extensive non-small-cell lung cancer: A prospective randomized study for the piedmont oncology association. Cancer. 47(12). 2827–2832. 6 indexed citations

19.

Cooper, M. Robert, et al.. (1972). Chronic granulomatous disease of childhood with onset of symptoms at age 11 years. The Journal of Pediatrics. 80(1). 104–106. 15 indexed citations

20.

DeChatelet, Lawrence R., M. Robert Cooper, & Charles E. McCall. (1970). Absence of Measurable Leukocyte Alkaline Phosphatase Activity from Leukocytes of Patients with Chronic Granulocytic Leukemia. Clinical Chemistry. 16(9). 798–799. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact